Market Overview:
The global gastrointestinal stromal tumor market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as increasing incidence of gastrointestinal stromal tumors, rising awareness about gastrointestinal stromal tumors, and technological advancements in the field of diagnosis and treatment of gastrointestinal stromal tumors. However, the high cost associated with diagnosis and treatment of gastrointestinal stromal tumors is likely to restrain the growth of this market during the forecast period. Based on type, the global gastrointestinal stromal tumor market can be segmented into stomach, small intestine, and others. The small intestine segment is expected to account for a major share of the global gastrointestinal stomatal tumor market during the forecast period owing to its high incidence rate.
Product Definition:
Gastrointestinal stromal tumor (GIST) is a rare type of cancer that begins in the cells of the digestive tract. GIST tumors can occur anywhere in the gastrointestinal tract, from the esophagus to the rectum. GIST tumors are most common in the stomach and small intestine.
Stomach:
Stomach is a hollow organ located in the upper part of the abdomen. It plays an important role in digestion and absorption of nutrients from food and helps maintain blood acidity levels. Stomach also has other functions such as it acts as a protective barrier against various infections, it manufactures stomach acids to help with digestion, absorbs vitamin B12 for proper functioning of the body along with helping with protein synthesis and lastly helps regulate heart function by regulating parietal cell production.
Small Intestine:
Small intestine is the part of gastrointestinal tract which includes duodenal bulb, ampulla and ileum. It is also known as small bowel or digestive tract. Small intestine serves many functions such as absorption of nutrients from food, re-processing of food materials for further use and protection against disease organisms.
Global Small Intestine.
Application Insights:
The other end users segment held the largest share of 60.0% in 2017. Other applications include research settings and private practices. Gastrointestinal stromal tumor (GIST) is a rare cancer that affects mostly the elderly population, thus making it difficult to obtain patient demographics for market analysis purposes. However, GIST clinics/hospitals account for a larger share in other end users as these tumors are more common among older people and require hospital-based treatment due to their advanced stage at diagnosis or progression during treatment at outpatient settings.
Clinics/specialized cancer treatment centers accounted for 39% of the total revenue generated by this market in 2017 owing to increasing awareness about early detection coupled with rising availability of treatments specific to gastrointestinal stromal tumor (GIST).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to increasing prevalence of gastrointestinal stromal tumors, rising awareness about GIST treatment options, and availability of effective treatment in this region. In addition, high adoption of technologically advanced medical products is also expected to drive the regional market during the forecast period.
Asia Pacific is anticipated to witness a lucrative growth rate over the forecast period owing to improving healthcare infrastructure and growing patient awareness about emerging treatments for various cancers including gastrointestinal stromal tumor (GIST). Moreover, government initiatives for cancer prevention are also contributing towards regional growth by creating awareness among people regarding early detection of these tumors. For instance, The Ministry Of Health And Family Welfare (MoHFW) has launched “Cancer Prevention & Control Program†which focuses on reducing population suffering from cancer through screening programs across India since 2015.
Growth Factors:
- Increasing incidence of gastrointestinal stromal tumor
- Growing awareness about gastrointestinal stromal tumor
- Rising demand for better treatment options for gastrointestinal stromal tumor
- Technological advancements in the diagnosis and treatment of gastrointestinal stromal tumor
- Availability of government funding for research on gastrointestinal stromal tumors
Scope Of The Report
Report Attributes
Report Details
Report Title
Gastrointestinal Stromal Tumor Market Research Report
By Type
Stomach, Small Intestine, Others
By Application
Hospitals, Clinics, Specialized Cancer Treatment Centers, Other End Users
By Companies
Novartis, Sun Pharmaceutical, Pfizer, Bayer Aktiengesellschaft, NATCO Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
221
Number of Tables & Figures
155
Customization Available
Yes, the report can be customized as per your need.
Global Gastrointestinal Stromal Tumor Market Report Segments:
The global Gastrointestinal Stromal Tumor market is segmented on the basis of:
Types
Stomach, Small Intestine, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Specialized Cancer Treatment Centers, Other End Users
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Sun Pharmaceutical
- Pfizer
- Bayer Aktiengesellschaft
- NATCO Pharma
Highlights of The Gastrointestinal Stromal Tumor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Stomach
- Small Intestine
- Others
- By Application:
- Hospitals
- Clinics
- Specialized Cancer Treatment Centers
- Other End Users
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gastrointestinal Stromal Tumor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gastrointestinal stromal tumors (GISTs) are a type of cancer that develops in the stomach, small intestine, or large intestine. GISTs are typically slow-growing tumors that can spread to other parts of the body. They can be difficult to diagnose and treat, but treatment options include surgery, chemotherapy, and radiation therapy.
Some of the major companies in the gastrointestinal stromal tumor market are Novartis, ​​Sun Pharmaceutical, Pfizer, Bayer Aktiengesellschaft, NATCO Pharma.
The gastrointestinal stromal tumor market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Gastrointestinal Stromal Tumor Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Gastrointestinal Stromal Tumor Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Gastrointestinal Stromal Tumor Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Gastrointestinal Stromal Tumor Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Gastrointestinal Stromal Tumor Market Size & Forecast, 2018-2028
4.5.1 Gastrointestinal Stromal Tumor Market Size and Y-o-Y Growth
4.5.2 Gastrointestinal Stromal Tumor Market Absolute $ Opportunity
Chapter 5 Global Gastrointestinal Stromal Tumor Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Gastrointestinal Stromal Tumor Market Size Forecast by Type
5.2.1 Stomach
5.2.2 Small Intestine
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Gastrointestinal Stromal Tumor Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Gastrointestinal Stromal Tumor Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Specialized Cancer Treatment Centers
6.2.4 Other End Users
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Gastrointestinal Stromal Tumor Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Gastrointestinal Stromal Tumor Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Gastrointestinal Stromal Tumor Analysis and Forecast
9.1 Introduction
9.2 North America Gastrointestinal Stromal Tumor Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Gastrointestinal Stromal Tumor Market Size Forecast by Type
9.6.1 Stomach
9.6.2 Small Intestine
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Gastrointestinal Stromal Tumor Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Specialized Cancer Treatment Centers
9.10.4 Other End Users
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Gastrointestinal Stromal Tumor Analysis and Forecast
10.1 Introduction
10.2 Europe Gastrointestinal Stromal Tumor Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Gastrointestinal Stromal Tumor Market Size Forecast by Type
10.6.1 Stomach
10.6.2 Small Intestine
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Gastrointestinal Stromal Tumor Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Specialized Cancer Treatment Centers
10.10.4 Other End Users
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Gastrointestinal Stromal Tumor Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Gastrointestinal Stromal Tumor Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Gastrointestinal Stromal Tumor Market Size Forecast by Type
11.6.1 Stomach
11.6.2 Small Intestine
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Gastrointestinal Stromal Tumor Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Specialized Cancer Treatment Centers
11.10.4 Other End Users
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Gastrointestinal Stromal Tumor Analysis and Forecast
12.1 Introduction
12.2 Latin America Gastrointestinal Stromal Tumor Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Gastrointestinal Stromal Tumor Market Size Forecast by Type
12.6.1 Stomach
12.6.2 Small Intestine
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Gastrointestinal Stromal Tumor Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Specialized Cancer Treatment Centers
12.10.4 Other End Users
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Gastrointestinal Stromal Tumor Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Gastrointestinal Stromal Tumor Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Gastrointestinal Stromal Tumor Market Size Forecast by Type
13.6.1 Stomach
13.6.2 Small Intestine
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Gastrointestinal Stromal Tumor Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Specialized Cancer Treatment Centers
13.10.4 Other End Users
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Gastrointestinal Stromal Tumor Market: Competitive Dashboard
14.2 Global Gastrointestinal Stromal Tumor Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Sun Pharmaceutical
14.3.3 Pfizer
14.3.4 Bayer Aktiengesellschaft
14.3.5 NATCO Pharma
